Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MECLOFENAMATE SODIUM vs ACULAR LS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.
Relief of mild to moderate acute pain,Treatment of primary dysmenorrhea,Management of osteoarthritis,Management of rheumatoid arthritis
FDA: Treatment of postoperative inflammation in patients who have undergone cataract surgery,Off-label: Relief of ocular pain, photophobia, and inflammation associated with corneal abrasion or refractive surgery
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
1 drop in the affected eye(s) four times daily
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
The terminal elimination half-life is approximately 1.8 hours (range 1.2–2.5 hours) following topical ocular administration. This short half-life is consistent with rapid clearance from the systemic circulation.
Primarily hepatic via cytochrome P450 enzymes, including CYP2C9 and CYP3A4.
Primarily hepatic via CYP2C9; undergoes glucuronidation and oxidation to inactive metabolites.
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Renal excretion of metabolites and unchanged drug accounts for approximately 26% of the dose. Fecal excretion accounts for approximately 74% of the dose, primarily as metabolites.
>99% (primarily to albumin)
Ketorolac is highly protein bound, approximately 99% bound to plasma proteins, primarily albumin.
0.5-1.0 L/kg (indicates extensive tissue distribution)
The volume of distribution is approximately 0.12 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
100% (oral, well absorbed)
Ophthalmic bioavailability is approximately 2% of the administered dose due to extensive nasolacrimal drainage and systemic absorption. Oral bioavailability of ketorolac is approximately 80-100%, but this route is not used for ophthalmic formulations.
e GFR 30-59 m L/min: use with caution, reduce dose by 50%; e GFR <30 m L/min: contraindicated.
No dosage adjustment required for renal impairment
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
No dosage adjustment required for hepatic impairment but use with caution in severe hepatic disease due to potential for increased systemic exposure
Not recommended for children under 14 years; for adolescents ≥14 years, same as adult dosing.
Safety and efficacy in pediatric patients below 2 years of age have not been established; for children 2 years and older, same as adult dosing
Initiate at lowest effective dose (50 mg twice daily); monitor renal function and GI bleeding risk.
No specific dose adjustment recommended; use with caution due to increased incidence of age-related ocular conditions
NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. Meclofenamate is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
None
Cardiovascular thrombotic events,Gastrointestinal bleeding, ulceration, and perforation,Hypertension and edema,Renal toxicity,Anaphylactoid reactions,Exacerbation of asthma,Hematologic toxicity including anemia,Hepatic enzyme elevations
Increased risk of bleeding and bleeding-related adverse events due to platelet inhibition,May prolong bleeding time,Cross-sensitivity with aspirin and other NSAIDs,Caution in patients with prior history of corneal epithelial defects or ocular surgery,Not for intraocular injection
Hypersensitivity to meclofenamate or any other NSAID,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Perioperative pain in setting of CABG surgery,Active peptic ulcer disease or gastrointestinal bleeding
Hypersensitivity to ketorolac tromethamine or any component of the formulation,Patients with active peptic ulcer disease, recent GI bleeding, or perforation,Patients with advanced renal disease or at risk for renal failure,Patients with known history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
Avoid high-fat meals as they may delay absorption. Limit salt intake to reduce fluid retention. Do not consume alcohol as it increases the risk of GI bleeding. Meclofenamate may decrease the effectiveness of diuretics and antihypertensive medications when taken with potassium-rich foods; monitor potassium levels.
No known food interactions for ophthalmic ketorolac. However, maintain good hydration and nutrition to support corneal healing.
Avoid in 1st and 2nd trimester; contraindicated in 3rd trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Associated with cardiovascular malformations if used in 1st trimester.
Ketorolac tromethamine, the active ingredient in ACULAR LS, is a nonsteroidal anti-inflammatory drug (NSAID). In animal reproduction studies, administration of ketorolac during organogenesis resulted in increased embryofetal mortality, delayed ossification, and increased incidence of skeletal abnormalities at doses less than the maximum recommended human ophthalmic dose. However, systemic exposure following ocular administration is very low. NSAIDs are generally avoided during pregnancy, especially in the third trimester, due to the risk of premature closure of the ductus arteriosus and oligohydramnios. The risk is considered low for ophthalmic use but should be used only if clearly needed.
Excreted into breast milk in small amounts; M/P ratio not established. Use caution due to potential adverse effects in neonates (e.g., gastrointestinal bleeding, platelet dysfunction).
It is not known whether ketorolac is excreted in human milk after ophthalmic administration. Systemic levels are low, and following oral administration, ketorolac is excreted in breast milk at low concentrations (M/P ratio approximately 0.37). Due to the potential for adverse effects on the nursing infant, caution should be exercised. The low systemic absorption likely poses minimal risk.
Increased plasma volume may require dose adjustments in 2nd and 3rd trimesters, but specific studies lacking; generally avoid use. If necessary, use lowest effective dose for shortest duration.
No dosing adjustments are necessary for ophthalmic use during pregnancy due to negligible systemic absorption. Standard dosing (1 drop in the affected eye(s) four times daily) is recommended. Systemic NSAIDs may require dose adjustment due to increased volume of distribution and renal changes, but this does not apply to topical ocular ketorolac.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) used for mild to moderate pain, dysmenorrhea, and inflammatory arthropathies. It has a higher incidence of gastrointestinal (GI) side effects, especially diarrhea, which can be dose-limiting. Monitor renal function and blood pressure, as it may cause fluid retention and worsening of hypertension. Use with caution in patients with a history of peptic ulcer disease or bleeding disorders. It is contraindicated in perioperative pain in coronary artery bypass graft (CABG) surgery.
ACULAR LS (ketorolac tromethamine ophthalmic solution 0.4%) is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the reduction of ocular pain and photophobia following corneal refractive surgery. Use with caution in patients with known bleeding tendencies or those on anticoagulants due to increased risk of ocular bleeding. Avoid concurrent use with other NSAIDs or steroids to minimize corneal adverse effects. Monitor for corneal epithelial breakdown or delayed healing.
Take with food or milk to reduce stomach upset.,Avoid alcohol and aspirin while taking this medication.,Report signs of GI bleeding (black, tarry stools; blood in vomit) immediately.,May cause diarrhea; notify your doctor if it becomes severe or persistent.,Do not take with other NSAIDs without consulting your doctor.,Stay hydrated, but avoid excessive salt intake to prevent fluid retention.,Inform your doctor if you have kidney disease, high blood pressure, or a history of stomach ulcers.,Do not use during pregnancy, especially in the third trimester.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 10 minutes before reinserting.,Use only in the affected eye(s) as prescribed; do not use for longer than directed.,Temporary stinging or burning may occur upon instillation.,Report any persistent pain, redness, or visual changes to your doctor immediately.,Avoid driving or operating machinery if vision is blurred after use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MECLOFENAMATE SODIUM vs ACULAR LS, answered by our medical review team.
MECLOFENAMATE SODIUM is a NSAID that works by Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.. ACULAR LS is a NSAID Ophthalmic that works by Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MECLOFENAMATE SODIUM and ACULAR LS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MECLOFENAMATE SODIUM is: 50 mg or 100 mg orally three times daily; maximum 400 mg/day.. The standard adult dose of ACULAR LS is: 1 drop in the affected eye(s) four times daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MECLOFENAMATE SODIUM and ACULAR LS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MECLOFENAMATE SODIUM is classified as Category C. Avoid in 1st and 2nd trimester; contraindicated in 3rd trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Associated w. ACULAR LS is classified as Category C. Ketorolac tromethamine, the active ingredient in ACULAR LS, is a nonsteroidal anti-inflammatory drug (NSAID). In animal reproduction studies, administration of ketorolac during org. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.